title: Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.
abstract: The widespread introduction of artemisinin-based combination therapy has contributed to recent reductions in malaria mortality. Combination therapies have a range of advantages, including synergism, toxicity reduction, and delaying the onset of resistance acquisition. Unfortunately, antimalarial combination therapy is limited by the depleting repertoire of effective drugs with distinct target pathways. To fast-track antimalarial drug discovery, we have previously employed drug-repositioning to identify the anti-amoebic drug, emetine dihydrochloride hydrate, as a potential candidate for repositioned use against malaria. Despite its 1000-fold increase in in vitro antimalarial potency (ED50 47 nM) compared with its anti-amoebic potency (ED50 26-32 uM), practical use of the compound has been limited by dose-dependent toxicity (emesis and cardiotoxicity). Identification of a synergistic partner drug would present an opportunity for dose-reduction, thus increasing the therapeutic window. The lack of reliable and standardised methodology to enable the in vitro definition of synergistic potential for antimalarials is a major drawback. Here we use isobologram and combination-index data generated by CalcuSyn software analyses (Biosoft v2.1) to define drug interactivity in an objective, automated manner. The method, based on the median effect principle proposed by Chou and Talalay, was initially validated for antimalarial application using the known synergistic combination (atovaquone-proguanil). The combination was used to further understand the relationship between SYBR Green viability and cytocidal versus cytostatic effects of drugs at higher levels of inhibition. We report here the use of the optimised Chou Talalay method to define synergistic antimalarial drug interactivity between emetine dihydrochloride hydrate and atovaquone. The novel findings present a potential route to harness the nanomolar antimalarial efficacy of this affordable natural product.
authors.affiliation: Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
authors.forename: Holly
authors.initials: H
authors.lastname: Matthews
authors.affiliation: Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
authors.forename: Jon
authors.initials: J
authors.lastname: Deakin
authors.affiliation: Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
authors.forename: May
authors.initials: M
authors.lastname: Rajab
authors.affiliation: Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
authors.forename: Maryam
authors.initials: M
authors.lastname: Idris-Usman
authors.affiliation: Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
authors.forename: Niroshini J
authors.identifier: http://orcid.org/0000-0001-9000-298X
authors.initials: NJ
authors.lastname: Nirmalan
mesh_terms: D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use; D053626:Atovaquone / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D019295:Computational Biology; D004338:Drug Combinations; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004640:Emetine / Q000627:therapeutic use*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000472:pathogenicity; D002727:Proguanil / Q000627:therapeutic use
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C109496:atovaquone, proguanil drug combination; D002738:Chloroquine; C031327:artemisinin; D002727:Proguanil; D004640:Emetine; D053626:Atovaquone